Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital therapeutic can be a valuable addition to clinician supervised medication-assisted treat...
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents PR Newswire UPPSALA, Sweden , June 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued ...
Orexo AB (ORXOY): Q1 GAAP EPS of -SEK0.92.Revenue of SEK132.3M (-24.4% Y/Y)Press Release For further details see: Orexo AB reports Q1 results
Orexo Q1 2021 Interim Report Investing in future growth drivers PR Newswire UPPSALA, Sweden , April 29, 2021 /PRNewswire/ -- Q1 2021 summary Total net revenues of SEK 132.3 m (175.0) Net earnings of SEK -31.5 m (82.6) EBITDA of ...
NEW YORK , March 19, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations an...
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management - The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percen...
Orexo calls for redemption of its outstanding bonds and obtains temporary waiver PR Newswire UPPSALA, Sweden , Feb. 5, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders ...
Orexo has successfully issued senior unsecured callable floating rate bonds PR Newswire UPPSALA, Sweden , Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable float...
Orexo contemplates issue of senior unsecured callable floating rate bonds PR Newswire UPPSALA, Sweden , Feb. 1, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series ...
Orexo AB (ORXOY) announces that it expects to file a New Drug Application for its Opioid overdose rescue drug OX124 with the US Food and Drug Administration by mid-2022.OX124 is expected to follow the FDA's standard submission and review timelines, as the FDA did not grant Fast...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...